Can I Take Resveratrol with Fosamax (Alendronate)?

What Is Alendronate and How Does It Work?

Alendronate is a nitrogen-containing bisphosphonate approved by the FDA for postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced bone loss [1]. It works by binding to hydroxyapatite on the bone surface and inhibiting osteoclast-mediated resorption. The drug's oral bioavailability is already very low, roughly 0.6 to 0.7% under fasting conditions [2].

Approved Doses and Schedule

The standard weekly regimen is 70 mg taken on a single morning each week. Daily dosing at 10 mg also exists, though weekly dosing has largely replaced it for adherence reasons. Patients must remain upright for at least 30 minutes after swallowing the tablet to reduce esophageal irritation risk, a requirement documented in the FDA prescribing information [1].

Why Absorption Is So Fragile

Even small deviations from strict fasting conditions destroy bioavailability. A pharmacokinetic study published in the Journal of Clinical Pharmacology found that co-administration of alendronate with coffee or orange juice reduced absorption by approximately 60%, and co-administration with food reduced it by roughly the same magnitude [3]. Plain water is the only acceptable co-ingestion fluid.

What Is Resveratrol and Why Do Bone-Health Patients Use It?

Resveratrol is a polyphenol found in red grape skins, berries, and Japanese knotweed (Polygonum cuspidatum). Supplement doses typically range from 150 mg to 1,000 mg per day. Postmenopausal women take it for cardiovascular and longevity reasons, and a growing body of preclinical data suggests it may support bone metabolism through estrogen-receptor binding and Sirt1/AMPK activation [4].

The SERM-Like Mechanism

Resveratrol binds estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) with moderate affinity, producing tissue-selective agonist or partial-agonist effects [5]. In osteoblast cultures, resveratrol at concentrations of 10 to 50 µM stimulated alkaline phosphatase activity and collagen synthesis, suggesting a pro-osteogenic signal [6]. Whether these concentrations are achievable in human bone tissue at oral supplement doses remains uncertain.

Human Trial Evidence on Bone

The REVResv trial (N=66 postmenopausal women) tested resveratrol 1,000 mg/day versus 150 mg/day versus placebo for 16 weeks. Lumbar spine bone mineral density (BMD) did not differ significantly between arms, but the high-dose group showed a statistically significant increase in alkaline phosphatase (a bone formation marker) compared with placebo [7]. This suggests a pharmacodynamic bone signal at doses above standard supplement ranges, though it does not confirm clinical fracture reduction.

Does Resveratrol Interact Pharmacokinetically with Alendronate?

No published pharmacokinetic trial has directly tested the resveratrol, alendronate combination in humans. The absence of a confirmed interaction does not mean the combination is risk-free; it means the interaction has not been adequately studied. Based on mechanism, the risk of a true pharmacokinetic interaction is low for two reasons outlined below.

Alendronate Is Not a CYP Substrate

Alendronate is excreted renally, unchanged, without hepatic CYP450 metabolism [2]. Resveratrol is a weak inhibitor of CYP3A4 and CYP2C9 in vitro, but because alendronate bypasses the CYP system entirely, enzyme inhibition by resveratrol is clinically irrelevant for alendronate clearance [8].

The Real Risk: Chelation and Absorption Competition

Resveratrol itself does not chelate calcium in the same way that dairy or antacids do, so it is not expected to reduce alendronate absorption through direct mineral binding. However, if a patient takes resveratrol capsules in the same sitting as alendronate, the act of swallowing additional pills often prompts reaching for water mixed with food or a morning smoothie, indirectly undermining the strict fasting protocol. Strict timing discipline matters more than the specific biochemistry of resveratrol itself.

Pharmacodynamic Considerations: Do Both Drugs Target Bone?

Pharmacodynamic interactions occur when two agents affect the same biological target, either additively or antagonistically. Both resveratrol and alendronate influence bone remodeling, but through different pathways.

Alendronate's Anti-Resorptive Mechanism

Alendronate inhibits farnesyl pyrophosphate synthase (FPPS) in osteoclasts, disrupting the mevalonate pathway and inducing osteoclast apoptosis [9]. The FIT trial (Fracture Intervention Trial, N=2,027) demonstrated that alendronate reduced vertebral fracture risk by 47% versus placebo over three years [10]. That is the clinical standard resveratrol must be measured against.

Resveratrol's Pro-Formation Signal

Resveratrol appears to act primarily on osteoblasts rather than osteoclasts, activating Sirt1 and RUNX2 transcription factors that drive bone formation [4]. In principle, an anti-resorptive agent (alendronate) combined with a pro-formation agent (resveratrol) could be complementary. No clinical trial has tested this combination directly, so the additive benefit remains speculative at present.

Estrogenic Activity and Breast Tissue

Postmenopausal women on alendronate for osteoporosis make up the majority of the drug's user population. Because resveratrol has SERM-like properties, long-term high-dose use could theoretically stimulate estrogen-sensitive tissues. A 2013 trial by Bowers et al. (N=29) found no increase in mammographic breast density after 12 weeks of resveratrol 500 mg twice daily, but the study was short and underpowered for oncological endpoints [11]. Women with personal or family history of hormone-receptor-positive breast cancer should discuss resveratrol supplementation with their oncologist before starting.

Timing Protocol: How to Take Both Safely

The most practical clinical point is this: separation by time is the cornerstone of safety for any supplement taken alongside alendronate.

Step-by-Step Morning Protocol

1. Wake up. Do not eat or drink anything except plain water.
2. Swallow alendronate 70 mg with 6 to 8 oz (180 to 240 mL) of plain water. No coffee, juice, mineral water, or other liquids.
3. Remain upright (sitting or standing) for at least 30 minutes, ideally 60 minutes.
4. After 30 to 60 minutes, eat breakfast.
5. Take resveratrol and any other supplements with or after breakfast.

This protocol satisfies the FDA-mandated fasting window for alendronate [1] while allowing resveratrol to be absorbed under fed conditions, which actually improves resveratrol's own bioavailability. A crossover pharmacokinetic study by Walle et al. Found that resveratrol's oral bioavailability, though low due to extensive first-pass glucuronidation, was not meaningfully harmed by food co-ingestion [12].

Weekly vs. Daily Dosing Implications

On weekly alendronate regimens, only one morning per week requires the strict fasting sequence. On the remaining six days, resveratrol timing is unrestricted. For daily 10 mg dosing, the fasting requirement applies every morning, making it more critical that patients build the supplement-delay habit consistently.

Resveratrol Dose Selection in an Osteoporosis Regimen

Not all resveratrol products are equivalent. Doses in published human trials range from 75 mg to 2,000 mg per day, and the regulatory status varies by country. The FDA classifies resveratrol as a dietary supplement, not a drug, meaning potency and purity are manufacturer-controlled [13].

What the Clinical Trials Used

The REVResv trial used 150 mg and 1,000 mg arms over 16 weeks [7]. A separate 2014 study by Ornstrup et al. (N=74 obese men) used resveratrol 1,000 mg/day for four months and found increased lumbar spine BMD compared with placebo (P<0.05), along with improved insulin sensitivity [14]. The bone finding has not been replicated in a larger, adequately powered trial.

Practical Dose Guidance

Most supplement-market products supply 100 to 500 mg per capsule. For patients on alendronate who want resveratrol for general cardiovascular or longevity reasons, 150 to 500 mg/day taken with breakfast is a reasonable starting range, pending any new guideline recommendations. Doses above 1,000 mg/day have produced mild gastrointestinal side effects (nausea, diarrhea) in some trial participants [7].

Monitoring Recommendations

Bone Mineral Density Surveillance

The American College of Obstetricians and Gynecologists (ACOG) recommends baseline DXA scanning for women aged 65 and older, or younger postmenopausal women with risk factors [15]. For patients on alendronate, follow-up DXA is typically performed every one to two years during active treatment and every two to three years once bone density has stabilized. Adding resveratrol does not change this monitoring schedule, but does make it more useful as a reference point: if BMD unexpectedly declines, reviewing supplement compliance and timing is one of the first troubleshooting steps.

Renal Function

Alendronate is renally cleared, and its prescribing information contraindicates use when creatinine clearance falls below 35 mL/min [1]. Resveratrol is not renally toxic at standard doses, but the combination should still prompt a baseline creatinine check in patients over 65, as renal function declines with age and affects alendronate dosing decisions.

Lab Panel Suggestions

At minimum, a clinician co-managing a patient on alendronate plus resveratrol should track:

• Serum calcium and 25-OH vitamin D (vitamin D adequacy is co-required for alendronate efficacy) [9]
• Creatinine and eGFR annually
• Bone turnover markers (serum CTX or urine NTX) if available, to verify anti-resorptive response
• Estradiol level in postmenopausal women if using high-dose resveratrol long-term, given its weak estrogenic activity [5]

Special Populations

Women With Hormone-Sensitive Conditions

Women with a history of hormone-receptor-positive breast cancer or endometrial hyperplasia should exercise particular caution with high-dose resveratrol. The Endocrine Society's clinical practice guideline on menopausal hormone therapy notes that even weak phytoestrogens can stimulate estrogen-responsive tissue in susceptible individuals [16]. This does not mean resveratrol is contraindicated in all such patients, but a shared decision-making conversation with an oncologist or gynecologist is warranted before starting.

Patients Also Taking Warfarin

Resveratrol inhibits CYP2C9, the primary metabolizing enzyme for warfarin [8]. While alendronate does not interact with warfarin, patients who take all three agents together could see elevated warfarin exposure and INR fluctuation. An INR check within two weeks of starting or substantially increasing resveratrol dose is prudent in anticoagulated patients.

Older Adults With Polypharmacy

Adults over 70 frequently take calcium, vitamin D, proton pump inhibitors (PPIs), and thiazide diuretics alongside alendronate. PPIs reduce gastric acid and may marginally decrease alendronate absorption, as noted in a pharmacokinetic analysis published in Alimentary Pharmacology and Therapeutics [17]. Resveratrol does not add meaningfully to this concern, but the overall supplement and medication list should be reviewed at every clinical encounter.

Summary of Interaction Classification

Based on the available evidence, the resveratrol, alendronate interaction can be classified as follows:

• Pharmacokinetic interaction: Not established. Alendronate has no CYP metabolism, so resveratrol's CYP3A4 and CYP2C9 inhibition is irrelevant.
• Absorption interference: Indirect risk only. Resveratrol itself does not chelate minerals, but poor morning dosing habits can undermine alendronate's absorption window.
• Pharmacodynamic interaction: Theoretically complementary (anti-resorptive plus pro-formation), but no clinical trial has confirmed additive benefit.
• Estrogenic signal: Clinically relevant at doses above 500 mg/day in hormone-sensitive populations; requires individualized assessment.

The FDA Adverse Event Reporting System (FAERS) does not list a notable resveratrol, alendronate signal as of the time of writing, though FAERS data underrepresent supplement-drug combinations [13].